O	0	12	Differential	Differential	JJ	B-NP
O	13	23	expression	expression	NN	I-NP
O	24	26	of	of	IN	B-PP
O	27	31	drug	drug	NN	B-NP
O	31	32	-	-	HYPH	B-NP
O	32	39	induced	induce	VBN	I-NP
O	40	44	drug	drug	NN	I-NP
O	45	52	targets	target	NNS	I-NP

O	53	64	Integrating	Integrate	VBG	B-VP
O	65	69	4849	4849	CD	B-NP
O	70	74	CMap	CMap	NN	I-NP
O	75	81	arrays	array	NNS	I-NP
O	82	86	with	with	IN	B-PP
O	87	89	40	40	CD	B-NP
O	89	90	,	,	,	I-NP
O	90	93	656	656	CD	I-NP
O	94	98	drug	drug	NN	I-NP
O	99	105	target	target	NN	I-NP
O	106	115	relations	relation	NNS	I-NP
O	116	120	from	from	IN	B-PP
O	121	127	STITCH	STITCH	NN	B-NP
O	128	136	resulted	result	VBD	B-VP
O	137	139	in	in	IN	B-PP
O	140	141	a	a	DT	B-NP
O	142	145	set	set	NN	I-NP
O	146	148	of	of	IN	B-PP
O	149	150	1	1	CD	B-NP
O	150	151	,	,	,	O
O	151	154	290	290	CD	B-NP
O	155	159	drug	drug	NN	I-NP
O	159	160	-	-	HYPH	B-NP
O	160	166	target	target	NN	I-NP
O	167	176	relations	relation	NNS	I-NP
O	177	180	for	for	IN	B-PP
O	181	186	which	which	WDT	B-NP
O	187	188	a	a	DT	B-NP
O	189	195	genome	genome	NN	I-NP
O	195	196	-	-	HYPH	B-NP
O	196	200	wide	wide	JJ	I-NP
B-Cell	201	209	cellular	cellular	JJ	I-NP
O	210	218	response	response	NN	I-NP
O	219	221	is	be	VBZ	B-VP
O	222	231	available	available	JJ	B-ADJP
O	231	232	.	.	.	O

O	233	235	We	We	PRP	B-NP
O	236	241	found	find	VBD	B-VP
O	242	246	that	that	IN	B-SBAR
O	247	255	thirteen	thirteen	CD	B-NP
O	256	259	out	out	IN	I-NP
O	260	262	of	of	IN	I-NP
O	263	266	167	167	CD	I-NP
O	267	275	distinct	distinct	JJ	I-NP
O	276	280	drug	drug	NN	I-NP
O	281	288	targets	target	NNS	I-NP
O	289	291	in	in	IN	B-PP
O	292	296	this	this	DT	B-NP
O	297	300	set	set	NN	I-NP
O	301	302	(	(	(	O
O	302	303	8	8	CD	B-NP
O	303	304	%	%	NN	I-NP
O	304	305	;	;	:	O
O	306	308	86	86	CD	B-NP
O	309	313	drug	drug	NN	I-NP
O	314	320	target	target	NN	I-NP
O	321	330	relations	relation	NNS	I-NP
O	330	331	)	)	)	O
O	332	335	are	be	VBP	B-VP
O	336	345	subjected	subject	VBN	I-VP
O	346	348	to	to	TO	B-PP
O	349	360	significant	significant	JJ	B-NP
O	361	373	differential	differential	JJ	I-NP
O	374	384	expression	expression	NN	I-NP
O	385	389	upon	upon	IN	B-PP
O	390	394	drug	drug	NN	B-NP
O	395	404	treatment	treatment	NN	I-NP
O	405	406	(	(	(	O
O	406	412	Figure	Figure	NN	B-NP
O	413	414	3	3	CD	I-NP
O	414	415	)	)	)	O
O	416	418	by	by	IN	B-PP
O	419	428	comparing	compare	VBG	B-VP
O	429	432	the	the	DT	B-NP
O	433	437	drug	drug	NN	I-NP
O	437	438	-	-	HYPH	B-VP
O	438	445	induced	induce	VBN	B-NP
O	446	456	expression	expression	NN	I-NP
O	457	464	changes	change	NNS	I-NP
O	465	467	of	of	IN	B-PP
O	468	471	the	the	DT	B-NP
O	472	476	drug	drug	NN	I-NP
O	477	483	target	target	NN	I-NP
O	484	491	against	against	IN	B-PP
O	492	495	all	all	DT	B-NP
O	496	501	other	other	JJ	I-NP
O	502	512	treatments	treatment	NNS	I-NP
O	513	520	present	present	JJ	B-ADJP
O	521	523	in	in	IN	B-PP
O	524	528	CMap	CMap	NN	B-NP
O	529	530	(	(	(	O
O	530	533	see	see	VB	B-VP
O	534	541	methods	method	NNS	B-NP
O	541	542	)	)	)	O
O	542	543	.	.	.	O

O	544	546	We	We	PRP	B-NP
O	547	552	found	find	VBD	B-VP
O	553	563	supporting	support	VBG	I-VP
O	564	572	evidence	evidence	NN	B-NP
O	573	575	in	in	IN	B-PP
O	576	579	the	the	DT	B-NP
O	580	590	literature	literature	NN	I-NP
O	591	594	for	for	IN	B-PP
O	595	600	seven	seven	CD	B-NP
O	601	604	out	out	IN	I-NP
O	605	607	of	of	IN	I-NP
O	608	616	thirteen	thirteen	CD	I-NP
O	617	618	(	(	(	O
O	618	619	q	q	NN	B-NP
O	619	620	-	-	HYPH	B-NP
O	620	625	value	value	NN	I-NP
O	626	627	<	<	SYM	B-NP
O	627	628	0	0	CD	B-NP
O	628	629	.	.	SYM	I-NP
O	629	631	05	05	CD	I-NP
O	631	632	)	)	)	O
O	633	644	significant	significant	JJ	B-NP
O	645	657	differential	differential	JJ	I-NP
O	658	669	regulations	regulation	NNS	I-NP
O	670	672	of	of	IN	B-PP
O	673	677	drug	drug	NN	B-NP
O	678	685	targets	target	NNS	I-NP
O	686	691	shown	show	VBN	B-VP
O	692	694	in	in	IN	B-PP
O	695	701	Figure	Figure	NN	B-NP
O	702	703	3	3	CD	I-NP
O	703	704	,	,	,	O
O	705	715	confirming	confirm	VBG	B-VP
O	716	719	the	the	DT	B-NP
O	720	729	rationale	rationale	NN	I-NP
O	730	733	and	and	CC	O
O	734	744	predictive	predictive	JJ	B-NP
O	745	750	power	power	NN	I-NP
O	751	753	of	of	IN	B-PP
O	754	757	our	our	PRP$	B-NP
O	758	768	systematic	systematic	JJ	I-NP
O	769	777	approach	approach	NN	I-NP
O	777	778	.	.	.	O

O	779	782	For	For	IN	B-PP
O	783	786	the	the	DT	B-NP
O	787	796	remaining	remain	VBG	I-NP
O	797	800	six	six	CD	I-NP
O	801	808	targets	target	NNS	I-NP
O	809	811	we	we	PRP	B-NP
O	812	815	can	can	MD	B-VP
O	816	823	predict	predict	VB	I-VP
O	824	825	a	a	DT	B-NP
O	826	834	hitherto	hitherto	RB	I-NP
O	835	842	unknown	unknown	JJ	I-NP
O	843	847	drug	drug	NN	I-NP
O	847	848	-	-	HYPH	O
O	848	855	induced	induce	VBN	B-NP
O	856	868	differential	differential	JJ	I-NP
O	869	879	regulation	regulation	NN	I-NP
O	879	880	.	.	.	O

O	881	883	10	10	CD	B-NP
O	883	884	.	.	.	I-NP
O	884	888	1371	1371	CD	I-NP
O	888	889	/	/	SYM	I-NP
O	889	896	journal	journal	NN	I-NP
O	896	897	.	.	SYM	I-NP
O	897	901	pcbi	pcbi	NN	I-NP
O	901	902	.	.	.	O
O	902	909	1000925	1000925	CD	B-NP
O	909	910	.	.	.	O
O	910	914	g003	g003	CD	B-NP
O	915	921	Figure	Figure	NNP	I-NP
O	922	923	3	3	CD	I-NP

O	924	928	Drug	Drug	NN	B-NP
O	928	929	-	-	HYPH	B-VP
O	929	936	induced	induce	VBN	B-NP
O	937	951	differentially	differentially	RB	I-NP
O	952	961	regulated	regulate	VBN	I-NP
O	962	966	drug	drug	NN	I-NP
O	967	974	targets	target	NNS	I-NP
O	974	975	.	.	.	O

O	976	981	Anova	Anova	NNP	B-NP
O	982	984	is	be	VBZ	B-VP
O	985	989	used	use	VBN	I-VP
O	990	992	to	to	TO	B-VP
O	993	999	assess	assess	VB	I-VP
O	1000	1003	the	the	DT	B-NP
O	1004	1016	significance	significance	NN	I-NP
O	1017	1019	of	of	IN	B-PP
O	1020	1023	the	the	DT	B-NP
O	1024	1036	differential	differential	JJ	I-NP
O	1037	1047	expression	expression	NN	I-NP
O	1048	1050	of	of	IN	B-PP
O	1051	1055	drug	drug	NN	B-NP
O	1055	1056	-	-	HYPH	B-NP
O	1056	1063	induced	induce	VBN	I-NP
O	1064	1068	drug	drug	NN	I-NP
O	1069	1076	targets	target	NNS	I-NP
O	1077	1084	against	against	IN	B-PP
O	1085	1088	the	the	DT	B-NP
O	1089	1093	mRNA	mRNA	NN	I-NP
O	1094	1101	changes	change	NNS	I-NP
O	1102	1104	of	of	IN	B-PP
O	1105	1108	the	the	DT	B-NP
O	1109	1113	same	same	JJ	I-NP
O	1114	1118	gene	gene	NN	I-NP
O	1119	1121	in	in	IN	B-PP
O	1122	1125	the	the	DT	B-NP
O	1126	1136	population	population	NN	I-NP
O	1137	1139	of	of	IN	B-PP
O	1140	1153	heterogeneous	heterogeneous	JJ	B-NP
O	1154	1158	drug	drug	NN	I-NP
O	1159	1169	treatments	treatment	NNS	I-NP
O	1170	1174	from	from	IN	B-PP
O	1175	1179	CMap	CMap	NN	B-NP
O	1179	1180	.	.	.	O

O	1181	1184	The	The	DT	B-NP
O	1185	1190	genes	gene	NNS	I-NP
O	1191	1194	are	be	VBP	B-VP
O	1195	1201	mainly	mainly	RB	I-VP
O	1202	1209	ordered	order	VBN	I-VP
O	1210	1215	based	base	VBN	B-PP
O	1216	1218	on	on	IN	B-PP
O	1219	1224	their	their	PRP$	B-NP
O	1225	1226	q	q	NN	I-NP
O	1226	1227	-	-	HYPH	O
O	1227	1233	values	value	NNS	B-NP
O	1234	1236	as	as	IN	B-SBAR
O	1237	1245	provided	provide	VBN	B-VP
O	1246	1248	in	in	IN	B-PP
O	1249	1254	Table	Table	JJ	B-NP
O	1255	1257	S1	S1	NN	I-NP
O	1257	1258	.	.	.	O

O	1259	1261	In	In	IN	B-PP
O	1262	1265	the	the	DT	B-NP
O	1266	1273	scatter	scatter	NN	I-NP
O	1274	1279	plots	plot	NNS	I-NP
O	1279	1280	,	,	,	O
O	1281	1291	inhibitors	inhibitor	NNS	B-NP
O	1291	1292	/	/	SYM	B-VP
O	1292	1302	activators	activator	NNS	B-NP
O	1303	1306	are	be	VBP	B-VP
O	1307	1314	labeled	label	VBN	I-VP
O	1315	1317	in	in	IN	B-PP
O	1318	1321	red	red	JJ	B-NP
O	1321	1322	/	/	SYM	I-NP
O	1322	1327	green	green	JJ	B-ADJP
O	1328	1340	respectively	respectively	RB	B-ADVP
O	1341	1344	and	and	CC	O
O	1345	1349	grey	grey	NN	B-NP
O	1350	1360	represents	represent	VBZ	B-VP
O	1361	1364	all	all	DT	B-NP
O	1365	1370	other	other	JJ	I-NP
O	1371	1381	treatments	treatment	NNS	I-NP
O	1382	1389	present	present	JJ	B-ADJP
O	1390	1392	in	in	IN	B-PP
O	1393	1397	CMap	CMap	NN	B-NP
O	1397	1398	.	.	.	O

O	1399	1402	The	The	DT	B-NP
O	1403	1413	identified	identify	VBN	I-NP
O	1413	1414	,	,	,	I-NP
O	1415	1429	differentially	differentially	RB	I-NP
O	1430	1439	regulated	regulate	VBN	I-NP
O	1440	1444	drug	drug	NN	I-NP
O	1445	1452	targets	target	NNS	I-NP
O	1453	1456	are	be	VBP	B-VP
O	1457	1465	enriched	enrich	VBN	I-VP
O	1466	1468	in	in	IN	B-PP
O	1469	1470	G	G	NN	B-NP
O	1470	1471	-	-	HYPH	B-NP
O	1471	1478	protein	protein	NN	I-NP
O	1479	1486	coupled	couple	VBN	B-NP
O	1487	1496	receptors	receptor	NNS	I-NP
O	1497	1498	(	(	(	O
O	1498	1503	GPCRs	GPCR	NNS	B-NP
O	1503	1504	)	)	)	O
O	1505	1506	(	(	(	O
O	1506	1512	Figure	Figure	NN	B-NP
O	1513	1515	S4	S4	NN	I-NP
O	1515	1516	)	)	)	O
O	1516	1517	,	,	,	O
O	1518	1520	in	in	IN	B-PP
O	1521	1530	agreement	agreement	NN	B-NP
O	1531	1535	with	with	IN	B-PP
O	1536	1544	previous	previous	JJ	B-NP
O	1545	1552	reports	report	NNS	I-NP
O	1553	1557	that	that	IN	B-SBAR
O	1558	1565	members	member	NNS	B-NP
O	1566	1568	of	of	IN	B-PP
O	1569	1572	the	the	DT	B-NP
O	1573	1577	GPCR	GPCR	NN	I-NP
O	1578	1584	family	family	NN	I-NP
O	1585	1588	are	be	VBP	B-VP
O	1589	1598	generally	generally	RB	I-VP
O	1599	1608	regulated	regulate	VBN	I-VP
O	1609	1611	by	by	IN	B-PP
O	1612	1619	several	several	JJ	B-NP
O	1620	1630	mechanisms	mechanism	NNS	I-NP
O	1631	1640	including	include	VBG	B-PP
O	1641	1649	receptor	receptor	NN	B-NP
O	1650	1665	desensitization	desensitization	NN	I-NP
O	1665	1666	,	,	,	O
O	1667	1678	endocytosis	endocytosis	NN	B-NP
O	1679	1681	at	at	IN	B-PP
O	1682	1685	the	the	DT	B-NP
O	1686	1693	protein	protein	NN	I-NP
O	1694	1699	level	level	NN	I-NP
O	1700	1703	and	and	CC	O
O	1704	1714	regulation	regulation	NN	B-NP
O	1715	1717	of	of	IN	B-PP
O	1718	1721	the	the	DT	B-NP
B-Cell	1722	1730	cellular	cellular	JJ	I-NP
O	1731	1739	receptor	receptor	NN	I-NP
O	1740	1747	content	content	NN	I-NP
O	1748	1749	[	[	(	O
O	1749	1751	18	18	CD	B-NP
O	1751	1752	]	]	)	O
O	1752	1753	,	,	,	O
O	1754	1755	[	[	(	O
O	1755	1757	19	19	CD	B-NP
O	1757	1758	]	]	)	O
O	1758	1759	.	.	.	O

O	1760	1762	In	In	IN	B-PP
O	1763	1766	the	the	DT	B-NP
O	1767	1772	three	three	CD	I-NP
B-Cell	1773	1779	cancer	cancer	NN	I-NP
I-Cell	1780	1784	cell	cell	NN	I-NP
I-Cell	1785	1790	lines	line	NNS	I-NP
O	1791	1795	used	use	VBN	B-VP
O	1795	1796	,	,	,	O
O	1797	1799	we	we	PRP	B-NP
O	1800	1807	observe	observe	VBP	B-VP
O	1808	1815	agonist	agonist	NN	B-NP
O	1815	1816	-	-	HYPH	O
O	1816	1823	induced	induce	VBN	B-VP
O	1824	1828	down	down	RB	B-ADVP
O	1828	1829	-	-	HYPH	B-NP
O	1829	1839	regulation	regulation	NN	I-NP
O	1840	1842	of	of	IN	B-PP
O	1843	1847	GPCR	GPCR	NN	B-NP
O	1848	1853	mRNAs	mRNA	NNS	I-NP
O	1854	1857	for	for	IN	B-PP
O	1858	1862	beta	beta	SYM	B-NP
O	1862	1863	-	-	HYPH	B-NP
O	1863	1864	2	2	CD	I-NP
O	1865	1875	adrenergic	adrenergic	JJ	I-NP
O	1876	1884	receptor	receptor	NN	I-NP
O	1885	1886	(	(	(	O
O	1886	1891	ADRB2	ADRB2	NN	B-NP
O	1891	1892	)	)	)	O
O	1892	1893	,	,	,	O
O	1894	1907	prostaglandin	prostaglandin	NN	B-NP
O	1908	1910	E2	E2	NN	I-NP
O	1911	1919	receptor	receptor	NN	I-NP
O	1920	1927	subtype	subtype	NN	I-NP
O	1928	1931	EP2	EP2	NN	I-NP
O	1932	1935	and	and	CC	O
O	1936	1949	prostaglandin	prostaglandin	NN	B-NP
O	1950	1952	E4	E4	NN	I-NP
O	1953	1961	receptor	receptor	NN	I-NP
O	1962	1969	subtype	subtype	NN	I-NP
O	1970	1973	EP4	EP4	NN	I-NP
O	1974	1975	(	(	(	O
O	1975	1981	Figure	Figure	NN	B-NP
O	1982	1983	3	3	CD	I-NP
O	1983	1984	,	,	,	O
O	1985	1990	Genes	Genes	NNP	B-NP
O	1991	1992	3	3	CD	I-NP
O	1992	1993	,	,	,	I-NP
O	1993	1994	4	4	CD	I-NP
O	1994	1995	,	,	,	I-NP
O	1995	1997	12	12	CD	I-NP
O	1997	1998	)	)	)	O
O	1998	1999	,	,	,	O
O	2000	2005	which	which	WDT	B-NP
O	2006	2010	were	be	VBD	B-VP
O	2011	2021	previously	previously	RB	I-VP
O	2022	2030	reported	report	VBN	I-VP
O	2031	2033	in	in	IN	B-PP
B-Cell	2034	2038	DDT1	DDT1	NN	B-NP
I-Cell	2039	2041	MF	MF	NN	I-NP
I-Cell	2041	2042	-	-	HYPH	B-NP
I-Cell	2042	2043	2	2	CD	I-NP
I-Cell	2044	2050	smooth	smooth	JJ	I-NP
I-Cell	2051	2057	muscle	muscle	NN	I-NP
I-Cell	2058	2063	cells	cell	NNS	I-NP
O	2064	2065	(	(	(	O
O	2065	2070	ADRB2	ADRB2	NN	B-NP
O	2070	2071	)	)	)	O
O	2072	2075	and	and	CC	O
B-Cell	2076	2079	293	293	CD	B-NP
I-Cell	2079	2080	-	-	HYPH	I-NP
I-Cell	2080	2084	EBNA	EBNA	NN	I-NP
I-Cell	2085	2090	human	human	JJ	I-NP
I-Cell	2091	2100	embryonic	embryonic	JJ	I-NP
I-Cell	2101	2107	kidney	kidney	NN	I-NP
I-Cell	2108	2113	cells	cell	NNS	I-NP
O	2114	2115	(	(	(	O
O	2115	2128	prostaglandin	prostaglandin	NN	B-NP
O	2129	2131	E2	E2	NN	I-NP
O	2131	2132	/	/	SYM	B-NP
O	2132	2134	E4	E4	NN	I-NP
O	2135	2143	receptor	receptor	NN	I-NP
O	2144	2152	subtypes	subtype	NNS	I-NP
O	2153	2156	EP2	EP2	NN	I-NP
O	2156	2157	/	/	SYM	B-NP
O	2157	2160	EP4	EP4	NN	I-NP
O	2160	2161	)	)	)	O
O	2162	2163	[	[	(	O
O	2163	2165	20	20	CD	B-NP
O	2165	2166	]	]	)	O
O	2166	2167	,	,	,	O
O	2168	2169	[	[	(	O
O	2169	2171	21	21	CD	B-NP
O	2171	2172	]	]	)	O
O	2172	2173	.	.	.	O

O	2174	2178	This	This	DT	B-NP
O	2179	2188	indicates	indicate	VBZ	B-VP
O	2189	2193	that	that	IN	B-SBAR
O	2194	2199	drugs	drug	NNS	B-NP
O	2200	2203	can	can	MD	B-VP
O	2204	2210	induce	induce	VB	I-VP
O	2211	2218	similar	similar	JJ	B-NP
O	2219	2227	feedback	feedback	NN	I-NP
O	2228	2233	loops	loop	VBZ	B-VP
O	2234	2236	in	in	IN	B-PP
O	2237	2238	a	a	DT	B-NP
O	2239	2243	wide	wide	JJ	I-NP
O	2244	2251	variety	variety	NN	I-NP
O	2252	2254	of	of	IN	B-PP
B-Cell	2255	2259	cell	cell	NN	B-NP
O	2260	2265	types	type	NNS	I-NP
O	2265	2266	.	.	.	O

O	2267	2274	However	However	RB	B-ADVP
O	2274	2275	,	,	,	O
O	2276	2278	we	we	PRP	B-NP
O	2279	2285	cannot	cannot	MD	B-VP
O	2286	2290	rule	rule	VB	I-VP
O	2291	2294	out	out	RP	B-PRT
O	2295	2299	that	that	IN	B-SBAR
O	2300	2305	cross	cross	AFX	B-NP
O	2305	2306	-	-	HYPH	I-NP
O	2306	2316	regulation	regulation	NN	I-NP
O	2317	2322	among	among	IN	B-PP
O	2323	2332	signaling	signaling	NN	B-NP
O	2333	2341	pathways	pathway	NNS	I-NP
O	2342	2345	may	may	MD	B-VP
O	2346	2348	be	be	VB	I-VP
O	2349	2360	responsible	responsible	JJ	B-ADJP
O	2361	2364	for	for	IN	B-PP
O	2365	2368	the	the	DT	B-NP
O	2369	2379	regulation	regulation	NN	I-NP
O	2380	2382	of	of	IN	B-PP
O	2383	2387	GPCR	GPCR	NN	B-NP
O	2388	2393	mRNAs	mRNA	NNS	I-NP
O	2394	2396	as	as	IN	B-SBAR
O	2397	2399	it	it	PRP	B-NP
O	2400	2403	has	have	VBZ	B-VP
O	2404	2408	been	be	VBN	I-VP
O	2409	2418	described	describe	VBN	I-VP
O	2419	2425	before	before	IN	B-PP
O	2426	2427	[	[	(	B-NP
O	2427	2429	22	22	CD	I-NP
O	2429	2430	]	]	)	O
O	2430	2431	.	.	.	O

O	2432	2435	For	For	IN	B-PP
O	2436	2443	example	example	NN	B-NP
O	2443	2444	,	,	,	O
O	2445	2447	it	it	PRP	B-NP
O	2448	2451	has	have	VBZ	B-VP
O	2452	2456	been	be	VBN	I-VP
O	2457	2462	shown	show	VBN	I-VP
O	2463	2467	that	that	IN	B-SBAR
O	2468	2469	a	a	DT	B-NP
O	2470	2474	beta	beta	NN	I-NP
O	2475	2485	adrenergic	adrenergic	JJ	I-NP
O	2486	2490	mRNA	mRNA	NN	I-NP
O	2490	2491	-	-	HYPH	B-PP
O	2491	2498	binding	bind	VBG	B-NP
O	2499	2506	protein	protein	NN	I-NP
O	2506	2507	,	,	,	O
O	2508	2512	ELAV	ELAV	NN	B-NP
O	2512	2513	-	-	HYPH	I-NP
O	2513	2517	like	like	JJ	I-NP
O	2518	2525	protein	protein	NN	I-NP
O	2526	2527	1	1	CD	I-NP
O	2528	2529	(	(	(	O
O	2529	2535	ELAVL1	ELAVL1	NN	B-NP
O	2535	2536	)	)	)	O
O	2537	2540	can	can	MD	B-VP
O	2541	2543	be	be	VB	I-VP
O	2544	2551	induced	induce	VBN	I-VP
O	2552	2554	by	by	IN	B-PP
O	2555	2560	ADRB2	ADRB2	NN	B-NP
O	2561	2568	agonist	agonist	NN	I-NP
O	2569	2571	or	or	CC	O
O	2572	2580	elevated	elevate	VBN	B-NP
O	2581	2587	levels	level	NNS	I-NP
O	2588	2590	of	of	IN	B-PP
O	2591	2597	cyclic	cyclic	JJ	B-NP
O	2598	2607	adenosine	adenosine	NN	I-NP
O	2608	2621	monophosphate	monophosphate	NN	I-NP
O	2622	2623	(	(	(	O
O	2623	2627	cAMP	cAMP	NN	B-NP
O	2627	2628	)	)	)	O
O	2629	2630	[	[	(	O
O	2630	2632	22	22	CD	B-NP
O	2632	2633	]	]	)	O
O	2633	2634	,	,	,	O
O	2635	2636	[	[	(	O
O	2636	2638	23	23	CD	B-NP
O	2638	2639	]	]	)	O
O	2640	2643	and	and	CC	O
O	2644	2656	destabilizes	destabilize	VBZ	B-VP
O	2657	2662	ADRB2	ADRB2	NN	B-NP
O	2663	2667	mRNA	mRNA	NN	I-NP
O	2667	2668	.	.	.	O

O	2669	2672	The	The	DT	B-NP
O	2673	2679	ELAVL1	ELAVL1	NN	I-NP
O	2680	2687	protein	protein	NN	I-NP
O	2688	2693	binds	bind	VBZ	B-VP
O	2694	2696	to	to	TO	B-PP
O	2697	2701	GPCR	GPCR	NN	B-NP
O	2702	2707	mRNAs	mRNA	NNS	I-NP
O	2708	2711	and	and	CC	O
O	2712	2722	recognizes	recognize	VBZ	B-VP
O	2723	2724	a	a	DT	B-NP
O	2725	2732	cognate	cognate	JJ	I-NP
O	2733	2741	sequence	sequence	NN	I-NP
O	2742	2749	located	located	JJ	B-ADJP
O	2750	2752	at	at	IN	B-PP
O	2753	2756	the	the	DT	B-NP
O	2757	2758	3	3	CD	I-NP
O	2758	2759	'	'	SYM	I-NP
O	2759	2760	-	-	HYPH	I-NP
O	2760	2763	UTR	UTR	NN	I-NP
O	2764	2766	of	of	IN	B-PP
O	2767	2772	ADRB2	ADRB2	NN	B-NP
O	2772	2773	,	,	,	O
O	2774	2784	proteinase	proteinase	NN	B-NP
O	2784	2785	-	-	HYPH	B-NP
O	2785	2794	activated	activate	VBN	I-NP
O	2795	2803	receptor	receptor	NN	I-NP
O	2804	2807	and	and	CC	I-NP
O	2808	2810	M2	M2	NN	I-NP
O	2810	2811	,	,	,	O
O	2812	2814	M3	M3	NN	B-NP
O	2815	2825	muscarinic	muscarinic	JJ	I-NP
O	2826	2839	acetylcholine	acetylcholine	NN	I-NP
O	2840	2848	receptor	receptor	NN	I-NP
O	2849	2854	mRNAs	mRNA	NNS	I-NP
O	2855	2856	[	[	(	O
O	2856	2858	24	24	CD	B-NP
O	2858	2859	]	]	)	O
O	2859	2860	,	,	,	O
O	2861	2862	[	[	(	O
O	2862	2864	25	25	CD	B-NP
O	2864	2865	]	]	)	O
O	2865	2866	.	.	.	O

O	2867	2876	Therefore	Therefore	RB	B-NP
O	2877	2881	cAMP	cAMP	NN	I-NP
O	2882	2890	provides	provide	VBZ	B-VP
O	2891	2896	cross	cross	AFX	B-NP
O	2896	2897	-	-	HYPH	I-NP
O	2897	2901	talk	talk	NN	B-NP
O	2902	2907	among	among	IN	B-PP
O	2908	2912	GPCR	GPCR	NN	B-NP
O	2913	2923	regulatory	regulatory	JJ	I-NP
O	2924	2932	networks	network	NNS	I-NP
O	2932	2933	.	.	.	O

O	2934	2941	However	However	RB	B-ADVP
O	2941	2942	,	,	,	O
O	2943	2945	it	it	PRP	B-NP
O	2946	2948	is	be	VBZ	B-VP
O	2949	2954	shown	show	VBN	I-VP
O	2955	2959	that	that	IN	B-SBAR
B-Immaterial_anatomical_entity	2960	2973	intracellular	intracellular	JJ	B-NP
O	2974	2978	cAMP	cAMP	NN	I-NP
O	2979	2991	accumulation	accumulation	NN	I-NP
O	2992	2994	is	be	VBZ	B-VP
O	2995	2998	not	not	RB	O
O	2999	3002	the	the	DT	B-NP
O	3003	3007	only	only	JJ	I-NP
O	3008	3014	factor	factor	NN	I-NP
O	3015	3027	contributing	contribute	VBG	B-VP
O	3028	3030	to	to	TO	B-PP
O	3031	3034	the	the	DT	B-NP
O	3035	3044	reduction	reduction	NN	I-NP
O	3045	3047	of	of	IN	B-PP
O	3048	3053	ADRB2	ADRB2	NN	B-NP
O	3054	3058	mRNA	mRNA	NN	I-NP
O	3059	3065	levels	level	NNS	I-NP
O	3066	3067	[	[	(	O
O	3067	3069	20	20	CD	B-NP
O	3069	3070	]	]	)	O
O	3070	3071	.	.	.	O

O	3072	3080	Moreover	Moreover	RB	B-ADVP
O	3080	3081	,	,	,	O
O	3082	3084	we	we	PRP	B-NP
O	3085	3089	find	find	VBP	B-VP
O	3090	3094	that	that	IN	B-SBAR
O	3095	3099	GPCR	GPCR	NN	B-NP
O	3099	3100	-	-	HYPH	O
O	3100	3109	targeting	target	VBG	B-VP
O	3110	3115	drugs	drug	NNS	B-NP
O	3116	3124	regulate	regulate	VBP	B-VP
O	3125	3128	the	the	DT	B-NP
O	3129	3142	transcription	transcription	NN	I-NP
O	3143	3145	of	of	IN	B-PP
O	3146	3151	their	their	PRP$	B-NP
O	3152	3160	specific	specific	JJ	I-NP
O	3161	3168	targets	target	NNS	I-NP
O	3169	3170	(	(	(	O
O	3170	3176	Figure	Figure	NN	B-NP
O	3177	3179	S5	S5	NN	I-NP
O	3179	3180	)	)	)	O
O	3180	3181	.	.	.	O

O	3182	3184	We	We	PRP	B-NP
O	3185	3193	conclude	conclude	VBP	B-VP
O	3194	3198	that	that	IN	B-SBAR
O	3199	3201	in	in	IN	B-PP
O	3202	3210	addition	addition	NN	B-NP
O	3211	3213	to	to	TO	B-PP
O	3214	3217	the	the	DT	B-NP
O	3218	3223	cross	cross	AFX	I-NP
O	3223	3224	-	-	HYPH	I-NP
O	3224	3234	regulation	regulation	NN	I-NP
O	3235	3237	of	of	IN	B-PP
O	3238	3239	G	G	NN	B-NP
O	3239	3240	-	-	HYPH	B-NP
O	3240	3247	protein	protein	NN	I-NP
O	3248	3257	signaling	signaling	NN	I-NP
O	3258	3266	pathways	pathway	NNS	I-NP
O	3267	3271	drug	drug	NN	I-NP
O	3272	3278	target	target	NN	I-NP
O	3278	3279	-	-	HYPH	B-NP
O	3279	3287	specific	specific	JJ	I-NP
O	3288	3296	feedback	feedback	NN	I-NP
O	3297	3302	loops	loop	NNS	I-NP
O	3303	3306	are	be	VBP	B-VP
O	3307	3311	also	also	RB	B-ADVP
O	3312	3323	responsible	responsible	JJ	B-ADJP
O	3324	3327	for	for	IN	B-PP
O	3328	3331	the	the	DT	B-NP
O	3332	3342	regulation	regulation	NN	I-NP
O	3343	3345	of	of	IN	B-PP
O	3346	3350	drug	drug	NN	B-NP
O	3351	3357	target	target	NN	I-NP
O	3358	3363	mRNAs	mRNA	NNS	I-NP
O	3363	3364	.	.	.	O

O	3365	3367	In	In	IN	B-PP
O	3368	3376	addition	addition	NN	B-NP
O	3377	3379	to	to	TO	B-PP
O	3380	3385	cross	cross	AFX	B-NP
O	3385	3386	-	-	HYPH	I-NP
O	3386	3396	regulation	regulation	NN	B-NP
O	3397	3399	of	of	IN	B-PP
O	3400	3408	multiple	multiple	JJ	B-NP
O	3409	3414	drugs	drug	NNS	I-NP
O	3415	3422	through	through	IN	B-PP
O	3423	3426	the	the	DT	B-NP
O	3427	3431	same	same	JJ	I-NP
O	3432	3441	signaling	signaling	NN	I-NP
O	3442	3450	pathways	pathway	NNS	I-NP
O	3450	3451	,	,	,	O
O	3452	3463	promiscuous	promiscuous	JJ	B-NP
O	3464	3469	drugs	drug	NNS	I-NP
O	3470	3479	targeting	target	VBG	B-VP
O	3480	3488	multiple	multiple	JJ	B-NP
O	3489	3497	proteins	protein	NNS	I-NP
O	3498	3501	may	may	MD	B-VP
O	3502	3507	cause	cause	VB	I-VP
O	3508	3515	complex	complex	JJ	B-NP
O	3516	3526	regulatory	regulatory	JJ	I-NP
O	3527	3535	networks	network	NNS	I-NP
O	3535	3536	.	.	.	O

O	3537	3539	In	In	IN	B-SBAR
O	3540	3545	order	order	NN	O
O	3546	3548	to	to	TO	B-VP
O	3549	3556	explore	explore	VB	I-VP
O	3557	3560	the	the	DT	B-NP
O	3561	3566	cross	cross	AFX	I-NP
O	3566	3567	-	-	HYPH	I-NP
O	3567	3577	regulation	regulation	NN	I-NP
O	3578	3580	of	of	IN	B-PP
O	3581	3585	drug	drug	NN	B-NP
O	3586	3593	targets	target	NNS	I-NP
O	3594	3601	induced	induce	VBN	B-VP
O	3602	3604	by	by	IN	B-PP
O	3605	3606	a	a	DT	B-NP
O	3607	3618	promiscuous	promiscuous	JJ	I-NP
O	3619	3623	drug	drug	NN	I-NP
O	3623	3624	,	,	,	O
O	3625	3627	we	we	PRP	B-NP
O	3628	3636	searched	search	VBD	B-VP
O	3637	3640	and	and	CC	O
O	3641	3646	found	find	VBD	B-VP
O	3647	3651	that	that	IN	B-SBAR
O	3652	3655	259	259	CD	B-NP
O	3656	3659	out	out	IN	B-PP
O	3660	3662	of	of	IN	B-PP
O	3663	3666	466	466	CD	B-NP
O	3667	3672	total	total	JJ	I-NP
O	3673	3678	drugs	drug	NNS	I-NP
O	3679	3682	are	be	VBP	B-VP
O	3683	3688	multi	multi	AFX	O
O	3688	3689	-	-	HYPH	B-NP
O	3689	3695	target	target	NN	I-NP
O	3696	3701	drugs	drug	NNS	I-NP
O	3702	3705	and	and	CC	O
O	3706	3707	4	4	CD	B-NP
O	3708	3710	of	of	IN	B-PP
O	3711	3716	these	these	DT	B-NP
O	3717	3722	drugs	drug	NNS	I-NP
O	3723	3726	act	act	VBP	B-VP
O	3727	3729	on	on	IN	B-PP
O	3730	3738	multiple	multiple	JJ	B-NP
O	3739	3753	differentially	differentially	RB	I-NP
O	3754	3763	regulated	regulate	VBN	I-NP
O	3764	3768	drug	drug	NN	I-NP
O	3769	3776	targets	target	NNS	I-NP
O	3777	3781	upon	upon	IN	B-PP
O	3782	3786	drug	drug	NN	B-NP
O	3787	3796	treatment	treatment	NN	I-NP
O	3796	3797	.	.	.	O

O	3798	3801	For	For	IN	B-PP
O	3802	3809	example	example	NN	B-NP
O	3809	3810	,	,	,	O
O	3811	3826	Podophyllotoxin	Podophyllotoxin	NN	B-NP
O	3827	3831	used	use	VBN	B-VP
O	3832	3834	in	in	IN	B-PP
O	3835	3842	various	various	JJ	B-NP
O	3843	3857	chemotherapies	chemotherapy	NNS	I-NP
O	3858	3860	is	be	VBZ	B-VP
O	3861	3866	known	know	VBN	I-VP
O	3867	3869	to	to	TO	I-VP
O	3870	3876	target	target	VB	I-VP
O	3877	3881	both	both	CC	O
O	3882	3889	tubulin	tubulin	NN	B-NP
O	3890	3894	beta	beta	NN	I-NP
O	3895	3897	2C	2C	NN	I-NP
O	3898	3901	and	and	CC	O
O	3902	3905	DNA	DNA	NN	B-NP
O	3906	3919	topoisomerase	topoisomerase	NN	I-NP
O	3920	3921	2	2	CD	I-NP
O	3921	3922	-	-	HYPH	O
O	3922	3927	alpha	alpha	SYM	B-NP
O	3927	3928	.	.	.	O

O	3929	3932	The	The	DT	B-NP
O	3933	3940	tubulin	tubulin	NN	I-NP
O	3941	3945	beta	beta	NN	I-NP
O	3946	3948	2C	2C	NN	I-NP
O	3949	3952	and	and	CC	O
O	3953	3956	DNA	DNA	NN	B-NP
O	3957	3970	topoisomerase	topoisomerase	NN	I-NP
O	3971	3972	2	2	CD	I-NP
O	3972	3973	-	-	HYPH	O
O	3973	3978	alpha	alpha	SYM	B-NP
O	3979	3984	mRNAs	mRNA	NNS	B-NP
O	3985	3988	are	be	VBP	B-VP
O	3989	3993	both	both	DT	O
O	3994	3998	down	down	RB	B-ADVP
O	3998	3999	-	-	HYPH	B-NP
O	3999	4008	regulated	regulate	VBN	B-VP
O	4009	4013	upon	upon	IN	B-PP
O	4014	4018	drug	drug	NN	B-NP
O	4019	4028	treatment	treatment	NN	I-NP
O	4029	4031	in	in	IN	B-PP
O	4032	4037	three	three	CD	B-NP
B-Cell	4038	4042	cell	cell	NN	I-NP
I-Cell	4043	4048	lines	line	NNS	I-NP
O	4049	4050	(	(	(	O
O	4050	4056	Figure	Figure	NN	B-NP
O	4057	4058	3	3	CD	I-NP
O	4058	4059	,	,	,	O
O	4060	4065	Genes	Genes	NNP	B-NP
O	4066	4067	8	8	CD	I-NP
O	4067	4068	,	,	,	I-NP
O	4068	4070	13	13	CD	I-NP
O	4070	4071	)	)	)	O
O	4071	4072	.	.	.	O

O	4073	4080	Tubulin	Tubulin	NN	B-NP
O	4081	4085	beta	beta	NN	I-NP
O	4086	4088	2C	2C	NN	I-NP
O	4089	4099	inhibitors	inhibitor	NNS	I-NP
O	4100	4106	induce	induce	VBP	B-VP
B-Cellular_component	4107	4118	microtubule	microtubule	NN	B-NP
O	4119	4135	depolymerization	depolymerization	NN	I-NP
O	4136	4140	that	that	WDT	B-NP
O	4141	4146	leads	lead	VBZ	B-VP
O	4147	4149	to	to	TO	B-PP
O	4150	4153	the	the	DT	B-NP
O	4154	4162	specific	specific	JJ	I-NP
O	4163	4167	down	down	RB	B-ADVP
O	4167	4168	-	-	HYPH	O
O	4168	4178	regulation	regulation	NN	B-NP
O	4179	4181	of	of	IN	B-PP
O	4182	4189	tubulin	tubulin	NN	B-NP
O	4190	4194	beta	beta	NN	I-NP
O	4195	4197	2C	2C	NN	I-NP
O	4198	4203	mRNAs	mRNA	NNS	I-NP
O	4204	4214	preventing	prevent	VBG	B-VP
O	4215	4218	the	the	DT	B-NP
O	4219	4232	translational	translational	JJ	I-NP
O	4233	4242	synthesis	synthesis	NN	I-NP
O	4243	4246	and	and	CC	O
O	4247	4251	thus	thus	RB	O
O	4252	4255	the	the	DT	B-NP
O	4256	4263	further	further	JJ	I-NP
O	4264	4276	accumulation	accumulation	NN	I-NP
O	4277	4279	of	of	IN	B-PP
O	4280	4288	abundant	abundant	JJ	B-NP
O	4289	4296	tubulin	tubulin	NN	I-NP
O	4297	4305	monomers	monomer	NNS	I-NP
O	4306	4307	[	[	(	O
O	4307	4309	26	26	CD	B-NP
O	4309	4310	]	]	)	O
O	4310	4311	.	.	.	O

O	4312	4320	Moreover	Moreover	RB	B-ADVP
O	4320	4321	,	,	,	O
O	4322	4324	we	we	PRP	B-NP
O	4325	4330	found	find	VBD	B-VP
O	4331	4335	that	that	IN	B-SBAR
O	4336	4339	DNA	DNA	NN	B-NP
O	4340	4353	topoisomerase	topoisomerase	NN	I-NP
O	4354	4355	2	2	CD	I-NP
O	4355	4356	-	-	HYPH	O
O	4356	4361	alpha	alpha	SYM	B-NP
O	4362	4367	mRNAs	mRNA	NNS	B-NP
O	4368	4371	are	be	VBP	B-VP
O	4372	4375	not	not	RB	O
O	4376	4380	down	down	RB	B-ADVP
O	4380	4381	-	-	HYPH	B-NP
O	4381	4390	regulated	regulate	VBN	B-VP
O	4391	4395	upon	upon	IN	B-PP
O	4396	4405	treatment	treatment	NN	B-NP
O	4406	4408	of	of	IN	B-PP
O	4409	4414	other	other	JJ	B-NP
O	4415	4422	tubulin	tubulin	NN	I-NP
O	4423	4433	inhibitors	inhibitor	NNS	I-NP
O	4434	4435	(	(	(	O
O	4435	4441	Figure	Figure	NN	B-NP
O	4442	4444	S5	S5	NN	I-NP
O	4444	4445	)	)	)	O
O	4445	4446	.	.	.	O

O	4447	4456	Therefore	Therefore	RB	B-ADVP
O	4456	4457	,	,	,	O
O	4458	4460	we	we	PRP	B-NP
O	4461	4469	conclude	conclude	VBP	B-VP
O	4470	4474	that	that	IN	B-SBAR
O	4475	4483	feedback	feedback	NN	B-NP
O	4484	4489	loops	loop	VBZ	B-VP
O	4490	4492	of	of	IN	B-PP
O	4493	4500	tubulin	tubulin	NN	B-NP
O	4501	4505	beta	beta	NN	I-NP
O	4506	4508	2C	2C	NN	I-NP
O	4509	4512	and	and	CC	O
O	4513	4516	DNA	DNA	NN	B-NP
O	4517	4530	topoisomerase	topoisomerase	NN	I-NP
O	4531	4532	2	2	CD	I-NP
O	4532	4533	-	-	HYPH	O
O	4533	4538	alpha	alpha	SYM	B-NP
O	4539	4542	are	be	VBP	B-VP
O	4543	4546	not	not	RB	O
O	4547	4552	cross	cross	AFX	B-ADJP
O	4552	4553	-	-	HYPH	O
O	4553	4562	regulated	regulate	VBN	B-VP
O	4562	4563	.	.	.	O

O	4564	4567	Two	Two	CD	B-NP
O	4568	4573	other	other	JJ	I-NP
O	4574	4582	examples	example	NNS	I-NP
O	4583	4585	of	of	IN	B-PP
O	4586	4591	multi	multi	AFX	B-NP
O	4591	4592	-	-	HYPH	I-NP
O	4592	4598	target	target	NN	I-NP
O	4599	4604	drugs	drug	NNS	I-NP
O	4605	4608	are	be	VBP	B-VP
O	4609	4619	vorinostat	vorinostat	NN	B-NP
O	4620	4624	used	use	VBN	B-VP
O	4625	4628	for	for	IN	B-PP
O	4629	4632	the	the	DT	B-NP
O	4633	4642	treatment	treatment	NN	I-NP
O	4643	4645	of	of	IN	B-PP
B-Cancer	4646	4655	cutaneous	cutaneous	JJ	B-NP
I-Cancer	4656	4657	T	T	NN	I-NP
I-Cancer	4658	4662	cell	cell	NN	I-NP
I-Cancer	4663	4671	lymphoma	lymphoma	NN	I-NP
O	4672	4675	and	and	CC	I-NP
O	4676	4688	trichostatin	trichostatin	NN	I-NP
O	4689	4690	A	A	NN	I-NP
O	4691	4695	that	that	WDT	B-NP
O	4696	4702	serves	serve	VBZ	B-VP
O	4703	4705	as	as	IN	B-PP
O	4706	4708	an	an	DT	B-NP
O	4709	4719	antifungal	antifungal	JJ	I-NP
O	4720	4730	antibiotic	antibiotic	NN	I-NP
O	4730	4731	.	.	.	O

O	4732	4742	Vorinostat	Vorinostat	NN	B-NP
O	4743	4746	and	and	CC	I-NP
O	4747	4759	trichostatin	trichostatin	NN	I-NP
O	4760	4761	A	A	NN	I-NP
O	4762	4765	are	be	VBP	B-VP
O	4766	4776	considered	consider	VBN	I-VP
O	4777	4779	to	to	TO	I-VP
O	4780	4782	be	be	VB	I-VP
O	4783	4794	nonspecific	nonspecific	JJ	B-NP
O	4795	4802	histone	histone	NN	I-NP
O	4803	4814	deacetylase	deacetylase	NN	I-NP
O	4815	4825	inhibitors	inhibitor	NNS	I-NP
O	4825	4826	.	.	.	O

O	4827	4832	These	These	DT	B-NP
O	4833	4838	drugs	drug	NNS	I-NP
O	4839	4843	lead	lead	VBP	B-VP
O	4844	4846	to	to	TO	B-PP
O	4847	4850	the	the	DT	B-NP
O	4851	4853	up	up	RB	I-NP
O	4853	4854	-	-	HYPH	I-NP
O	4854	4864	regulation	regulation	NN	I-NP
O	4865	4867	of	of	IN	B-PP
O	4868	4875	histone	histone	NN	B-NP
O	4876	4887	deacetylase	deacetylase	NN	I-NP
O	4888	4889	3	3	CD	I-NP
O	4890	4891	(	(	(	O
O	4891	4896	HDAC3	HDAC3	NN	B-NP
O	4896	4897	)	)	)	O
O	4898	4901	and	and	CC	O
O	4902	4906	down	down	RB	B-ADVP
O	4906	4907	-	-	HYPH	O
O	4907	4917	regulation	regulation	NN	B-NP
O	4918	4920	of	of	IN	B-PP
O	4921	4928	histone	histone	NN	B-NP
O	4929	4940	deacetylase	deacetylase	NN	I-NP
O	4941	4942	7	7	CD	I-NP
O	4943	4944	(	(	(	O
O	4944	4949	HDAC7	HDAC7	NN	B-NP
O	4949	4950	)	)	)	O
O	4951	4952	(	(	(	O
O	4952	4958	Figure	Figure	NN	B-NP
O	4959	4960	3	3	CD	I-NP
O	4960	4961	,	,	,	O
O	4962	4967	Genes	Genes	NNP	B-NP
O	4968	4969	1	1	CD	I-NP
O	4969	4970	,	,	,	I-NP
O	4970	4971	5	5	CD	I-NP
O	4971	4972	)	)	)	O
O	4972	4973	.	.	.	O

O	4974	4976	In	In	IN	B-PP
O	4977	4981	this	this	DT	B-NP
O	4982	4986	case	case	NN	I-NP
O	4987	4989	it	it	PRP	B-NP
O	4990	4992	is	be	VBZ	B-VP
O	4993	5000	unclear	unclear	JJ	B-ADJP
O	5001	5008	whether	whether	IN	B-SBAR
O	5009	5014	there	there	EX	B-NP
O	5015	5017	is	be	VBZ	B-VP
O	5018	5023	cross	cross	AFX	B-NP
O	5023	5024	-	-	HYPH	I-NP
O	5024	5034	regulation	regulation	NN	B-NP
O	5034	5035	,	,	,	O
O	5036	5044	although	although	IN	B-SBAR
O	5045	5050	HDAC7	HDAC7	NN	B-NP
O	5051	5056	siRNA	siRNA	NN	I-NP
O	5057	5068	experiments	experiment	NNS	I-NP
O	5069	5075	failed	fail	VBD	B-VP
O	5076	5078	to	to	TO	I-VP
O	5079	5085	induce	induce	VB	I-VP
O	5086	5089	the	the	DT	B-NP
O	5090	5092	up	up	RB	I-NP
O	5092	5093	-	-	HYPH	I-NP
O	5093	5103	regulation	regulation	NN	B-NP
O	5104	5106	of	of	IN	B-PP
O	5107	5112	HDAC3	HDAC3	NN	B-NP
O	5113	5118	mRNAs	mRNA	NNS	I-NP
O	5119	5120	[	[	(	O
O	5120	5122	27	27	CD	B-NP
O	5122	5123	]	]	)	O
O	5123	5124	,	,	,	O
O	5125	5126	a	a	DT	B-NP
O	5127	5133	result	result	NN	I-NP
O	5134	5138	that	that	WDT	B-NP
O	5139	5141	is	be	VBZ	B-VP
O	5142	5153	disfavoring	disfavor	VBG	I-VP
O	5154	5157	the	the	DT	B-NP
O	5158	5163	cross	cross	AFX	I-NP
O	5163	5164	-	-	HYPH	I-NP
O	5164	5174	regulation	regulation	NN	I-NP
O	5174	5175	.	.	.	O

O	5176	5181	While	While	IN	B-SBAR
O	5182	5185	the	the	DT	B-NP
O	5186	5191	above	above	JJ	I-NP
O	5192	5197	cases	case	NNS	I-NP
O	5198	5202	only	only	RB	B-ADVP
O	5203	5210	confirm	confirm	VBP	B-VP
O	5211	5221	literature	literature	NN	B-NP
O	5222	5229	reports	report	NNS	I-NP
O	5230	5232	in	in	IN	B-PP
O	5233	5238	other	other	JJ	B-NP
B-Cell	5239	5243	cell	cell	NN	I-NP
I-Cell	5244	5249	lines	line	NNS	I-NP
O	5250	5252	or	or	CC	O
B-Tissue	5253	5260	tissues	tissue	NNS	B-NP
O	5260	5261	,	,	,	O
O	5262	5264	we	we	PRP	B-NP
O	5265	5269	also	also	RB	B-ADVP
O	5270	5280	identified	identify	VBD	B-VP
O	5281	5284	new	new	JJ	B-NP
O	5285	5290	cases	case	NNS	I-NP
O	5291	5293	of	of	IN	B-PP
O	5294	5298	drug	drug	NN	B-NP
O	5298	5299	-	-	HYPH	B-NP
O	5299	5306	induced	induce	VBN	I-NP
O	5307	5317	expression	expression	NN	I-NP
O	5318	5328	regulation	regulation	NN	I-NP
O	5329	5331	of	of	IN	B-PP
O	5332	5336	drug	drug	NN	B-NP
O	5337	5344	targets	target	NNS	I-NP
O	5344	5345	.	.	.	O

O	5346	5349	The	The	DT	B-NP
O	5350	5361	significant	significant	JJ	I-NP
O	5362	5367	novel	novel	JJ	I-NP
O	5368	5376	findings	finding	NNS	I-NP
O	5377	5380	are	be	VBP	B-VP
O	5381	5384	the	the	DT	B-NP
O	5385	5394	inhibitor	inhibitor	NN	I-NP
O	5394	5395	-	-	HYPH	O
O	5395	5402	induced	induce	VBN	B-VP
O	5403	5407	down	down	RB	B-ADVP
O	5407	5408	-	-	HYPH	B-NP
O	5408	5418	regulation	regulation	NN	I-NP
O	5419	5421	of	of	IN	B-PP
O	5422	5432	calmodulin	calmodulin	NN	B-NP
O	5433	5434	1	1	CD	I-NP
O	5434	5435	,	,	,	O
O	5436	5439	DNA	DNA	NN	B-NP
O	5440	5453	topoisomerase	topoisomerase	NN	I-NP
O	5454	5455	2	2	CD	I-NP
O	5455	5456	-	-	HYPH	O
O	5456	5461	alpha	alpha	SYM	B-NP
O	5462	5465	and	and	CC	O
O	5466	5468	up	up	RB	B-ADVP
O	5468	5469	-	-	HYPH	B-NP
O	5469	5479	regulation	regulation	NN	I-NP
O	5480	5482	of	of	IN	B-PP
O	5483	5494	endoplasmin	endoplasmin	NN	B-NP
O	5494	5495	,	,	,	O
O	5496	5506	lanosterol	lanosterol	NN	B-NP
O	5507	5509	14	14	CD	I-NP
O	5509	5510	-	-	HYPH	I-NP
O	5510	5515	alpha	alpha	NN	I-NP
O	5516	5527	demethylase	demethylase	NN	I-NP
O	5528	5531	and	and	CC	I-NP
O	5532	5536	cAMP	cAMP	NN	I-NP
O	5536	5537	-	-	HYPH	B-NP
O	5537	5545	specific	specific	JJ	I-NP
O	5546	5563	phosphodiesterase	phosphodiesterase	NN	I-NP
O	5564	5566	4D	4D	NN	I-NP
O	5567	5568	(	(	(	O
O	5568	5574	Figure	Figure	NN	B-NP
O	5575	5576	3	3	CD	I-NP
O	5576	5577	,	,	,	O
O	5578	5583	Genes	Genes	NNP	B-NP
O	5584	5585	9	9	CD	I-NP
O	5585	5586	,	,	,	I-NP
O	5586	5587	8	8	CD	I-NP
O	5587	5588	,	,	,	I-NP
O	5588	5589	2	2	CD	I-NP
O	5589	5590	,	,	,	I-NP
O	5590	5591	7	7	CD	I-NP
O	5591	5592	,	,	,	I-NP
O	5592	5594	10	10	CD	I-NP
O	5594	5595	)	)	)	O
O	5595	5596	.	.	.	O

O	5597	5607	Lanosterol	Lanosterol	NN	B-NP
O	5608	5610	14	14	CD	I-NP
O	5610	5611	-	-	HYPH	I-NP
O	5611	5616	alpha	alpha	NN	I-NP
O	5617	5628	demethylase	demethylase	NN	I-NP
O	5629	5631	is	be	VBZ	B-VP
O	5632	5640	actually	actually	RB	B-ADVP
O	5641	5643	an	an	DT	B-NP
O	5644	5647	off	off	RB	I-NP
O	5647	5648	-	-	HYPH	I-NP
O	5648	5654	target	target	NN	I-NP
O	5655	5657	of	of	IN	B-PP
O	5658	5668	antifungal	antifungal	JJ	B-NP
O	5669	5674	drugs	drug	NNS	I-NP
O	5675	5679	that	that	WDT	B-NP
O	5680	5684	bind	bind	VBP	B-VP
O	5685	5688	the	the	DT	B-NP
O	5689	5698	mammalian	mammalian	JJ	I-NP
O	5699	5706	version	version	NN	I-NP
O	5707	5711	with	with	IN	B-PP
O	5712	5717	lower	low	JJR	B-NP
O	5718	5726	affinity	affinity	NN	I-NP
O	5727	5731	than	than	IN	B-PP
O	5732	5735	the	the	DT	B-NP
O	5736	5742	fungal	fungal	JJ	I-NP
O	5743	5753	lanosterol	lanosterol	NN	I-NP
O	5754	5756	14	14	CD	I-NP
O	5756	5757	-	-	HYPH	I-NP
O	5757	5762	alpha	alpha	NN	I-NP
O	5763	5774	demethylase	demethylase	NN	I-NP
O	5774	5775	.	.	.	O

O	5776	5784	Probably	Probably	RB	B-ADVP
O	5784	5785	,	,	,	O
O	5786	5789	the	the	DT	B-NP
O	5790	5792	up	up	RB	I-NP
O	5792	5793	-	-	HYPH	I-NP
O	5793	5803	regulation	regulation	NN	I-NP
O	5804	5806	of	of	IN	B-PP
O	5807	5810	the	the	DT	B-NP
O	5811	5820	mammalian	mammalian	JJ	I-NP
O	5821	5831	lanosterol	lanosterol	NN	I-NP
O	5832	5834	14	14	CD	I-NP
O	5834	5835	-	-	HYPH	B-NP
O	5835	5840	alpha	alpha	SYM	I-NP
O	5841	5852	demethylase	demethylase	NN	I-NP
O	5853	5864	compensates	compensate	NNS	I-NP
O	5865	5868	for	for	IN	B-PP
O	5869	5872	the	the	DT	B-NP
O	5873	5882	undesired	undesired	JJ	I-NP
O	5883	5893	inhibition	inhibition	NN	I-NP
O	5894	5897	and	and	CC	O
O	5898	5907	modulates	modulate	VBZ	B-VP
O	5908	5911	the	the	DT	B-NP
O	5912	5919	adverse	adverse	JJ	I-NP
O	5920	5927	effects	effect	NNS	I-NP
O	5927	5928	.	.	.	O

O	5929	5931	On	On	IN	B-PP
O	5932	5935	the	the	DT	B-NP
O	5936	5944	contrary	contrary	NN	I-NP
O	5944	5945	,	,	,	O
O	5946	5948	we	we	PRP	B-NP
O	5949	5957	observed	observe	VBD	B-VP
O	5958	5959	a	a	DT	B-NP
O	5960	5968	feedback	feedback	NN	I-NP
O	5969	5973	loop	loop	NN	I-NP
O	5974	5978	that	that	WDT	B-NP
O	5979	5990	accelerates	accelerate	VBZ	B-VP
O	5991	5994	the	the	DT	B-NP
O	5995	5999	down	down	JJ	I-NP
O	6000	6010	regulation	regulation	NN	I-NP
O	6011	6013	of	of	IN	B-PP
O	6014	6024	calmodulin	calmodulin	NN	B-NP
O	6025	6026	1	1	CD	I-NP
O	6027	6031	mRNA	mRNA	NN	I-NP
O	6032	6039	induced	induce	VBN	B-VP
O	6040	6042	by	by	IN	B-PP
O	6043	6053	calmodulin	calmodulin	NN	B-NP
O	6054	6064	inhibitors	inhibitor	NNS	I-NP
O	6064	6065	.	.	.	O

O	6066	6076	Calmodulin	Calmodulin	NN	B-NP
O	6077	6086	targeting	target	VBG	I-NP
O	6087	6092	drugs	drug	NNS	I-NP
O	6093	6096	can	can	MD	B-VP
O	6097	6104	provide	provide	VB	I-VP
O	6105	6106	a	a	DT	B-NP
O	6107	6112	rapid	rapid	JJ	I-NP
O	6113	6116	and	and	CC	I-NP
O	6117	6126	effective	effective	JJ	I-NP
O	6127	6138	therapeutic	therapeutic	JJ	I-NP
O	6139	6145	effect	effect	NN	I-NP
O	6145	6146	,	,	,	O
O	6147	6152	while	while	IN	B-SBAR
O	6153	6155	at	at	IN	B-PP
O	6156	6159	the	the	DT	B-NP
O	6160	6164	same	same	JJ	I-NP
O	6165	6169	time	time	NN	I-NP
O	6170	6175	small	small	JJ	B-NP
O	6176	6186	variations	variation	NNS	I-NP
O	6187	6189	of	of	IN	B-PP
O	6190	6194	drug	drug	NN	B-NP
O	6195	6209	concentrations	concentration	NNS	I-NP
O	6210	6213	can	can	MD	B-VP
O	6214	6222	increase	increase	VB	I-VP
O	6223	6230	adverse	adverse	JJ	B-NP
O	6231	6238	effects	effect	NNS	I-NP
O	6238	6239	.	.	.	O

O	6240	6249	Therefore	Therefore	RB	B-ADVP
O	6249	6250	,	,	,	O
O	6251	6253	it	it	PRP	B-NP
O	6254	6259	would	would	MD	B-VP
O	6260	6262	be	be	VB	I-VP
O	6263	6274	interesting	interesting	JJ	B-ADJP
O	6275	6277	to	to	TO	B-VP
O	6278	6283	study	study	VB	I-VP
O	6284	6291	further	further	RBR	B-ADVP
O	6292	6295	the	the	DT	B-NP
O	6296	6306	functional	functional	JJ	I-NP
O	6307	6314	effects	effect	NNS	I-NP
O	6315	6319	upon	upon	IN	B-PP
O	6320	6326	target	target	NN	B-NP
O	6327	6337	inhibition	inhibition	NN	I-NP
O	6338	6340	of	of	IN	B-PP
O	6341	6351	lanosterol	lanosterol	NN	B-NP
O	6352	6354	14	14	CD	I-NP
O	6354	6355	-	-	HYPH	I-NP
O	6355	6360	alpha	alpha	NN	I-NP
O	6361	6372	demethylase	demethylase	NN	I-NP
O	6372	6373	,	,	,	O
O	6374	6385	endoplasmin	endoplasmin	NN	B-NP
O	6386	6389	and	and	CC	O
O	6390	6400	calmodulin	calmodulin	NN	B-NP
O	6401	6402	1	1	CD	I-NP
O	6403	6405	to	to	TO	B-VP
O	6406	6415	elucidate	elucidate	VB	I-VP
O	6416	6419	the	the	DT	B-NP
O	6420	6425	roles	role	NNS	I-NP
O	6426	6428	of	of	IN	B-PP
O	6429	6437	feedback	feedback	NN	B-NP
O	6438	6443	loops	loop	VBZ	B-VP
O	6444	6446	in	in	IN	B-PP
O	6447	6451	drug	drug	NN	B-NP
O	6452	6456	mode	mode	NN	I-NP
O	6457	6459	of	of	IN	B-PP
O	6460	6466	action	action	NN	B-NP
O	6467	6470	and	and	CC	O
O	6471	6478	adverse	adverse	JJ	B-NP
O	6479	6486	effects	effect	NNS	I-NP
O	6486	6487	.	.	.	O

O	6488	6492	Drug	Drug	NN	B-NP
O	6492	6493	-	-	HYPH	B-NP
O	6493	6500	induced	induce	VBN	I-NP
O	6501	6507	target	target	NN	I-NP
O	6508	6518	regulation	regulation	NN	I-NP
O	6519	6524	might	might	MD	B-VP
O	6525	6527	be	be	VB	I-VP
O	6528	6538	implicated	implicate	VBN	I-VP
O	6539	6541	in	in	IN	B-PP
O	6542	6551	tolerance	tolerance	NN	B-NP
O	6552	6563	development	development	NN	I-NP
O	6564	6567	and	and	CC	O
O	6568	6572	thus	thus	RB	B-ADVP
O	6573	6584	identifying	identify	VBG	B-VP
O	6585	6594	potential	potential	JJ	B-NP
O	6595	6601	target	target	NN	I-NP
O	6602	6612	regulation	regulation	NN	I-NP
O	6613	6619	should	should	MD	B-VP
O	6620	6622	be	be	VB	I-VP
O	6623	6625	an	an	DT	B-NP
O	6626	6634	integral	integral	JJ	I-NP
O	6635	6639	part	part	NN	I-NP
O	6640	6642	of	of	IN	B-PP
O	6643	6647	drug	drug	NN	B-NP
O	6648	6657	discovery	discovery	NN	I-NP
O	6658	6660	to	to	TO	B-VP
O	6661	6668	prevent	prevent	VB	I-VP
O	6669	6677	failures	failure	NNS	B-NP
O	6678	6680	in	in	IN	B-PP
O	6681	6686	later	later	JJ	B-NP
O	6687	6693	stages	stage	NNS	I-NP
O	6694	6696	of	of	IN	B-PP
O	6697	6705	clinical	clinical	JJ	B-NP
O	6706	6712	trials	trial	NNS	I-NP
O	6712	6713	.	.	.	O

O	6714	6717	For	For	IN	B-PP
O	6718	6725	example	example	NN	B-NP
O	6725	6726	,	,	,	O
O	6727	6729	we	we	PRP	B-NP
O	6730	6734	have	have	VBP	B-VP
O	6735	6743	observed	observe	VBN	I-VP
O	6744	6747	the	the	DT	B-NP
O	6748	6757	inhibitor	inhibitor	NN	I-NP
O	6757	6758	-	-	HYPH	O
O	6758	6765	induced	induce	VBN	B-VP
O	6766	6768	up	up	RB	B-ADVP
O	6768	6769	-	-	HYPH	B-NP
O	6769	6779	regulation	regulation	NN	I-NP
O	6780	6782	of	of	IN	B-PP
O	6783	6788	ADRB2	ADRB2	NN	B-NP
O	6789	6792	and	and	CC	O
O	6793	6804	thymidylate	thymidylate	NN	B-NP
O	6805	6815	synthetase	synthetase	NN	I-NP
O	6816	6817	(	(	(	O
O	6817	6821	TYMS	TYMS	NN	B-NP
O	6821	6822	)	)	)	O
O	6822	6823	(	(	(	O
O	6823	6829	Figure	Figure	NN	B-NP
O	6830	6831	3	3	CD	I-NP
O	6831	6832	,	,	,	O
O	6833	6838	Genes	Genes	NNP	B-NP
O	6839	6840	3	3	CD	I-NP
O	6840	6841	,	,	,	I-NP
O	6841	6843	11	11	CD	I-NP
O	6843	6844	)	)	)	O
O	6845	6846	[	[	(	O
O	6846	6848	28	28	CD	B-NP
O	6848	6849	]	]	)	O
O	6849	6850	.	.	.	O

O	6851	6855	TYMS	TYMS	NN	B-NP
O	6856	6858	is	be	VBZ	B-VP
O	6859	6861	an	an	DT	B-NP
O	6862	6871	essential	essential	JJ	I-NP
O	6872	6878	enzyme	enzyme	NN	I-NP
O	6879	6882	for	for	IN	B-PP
O	6883	6886	DNA	DNA	NN	B-NP
O	6887	6898	replication	replication	NN	I-NP
O	6898	6899	/	/	SYM	B-NP
O	6899	6905	repair	repair	NN	I-NP
O	6906	6909	and	and	CC	O
O	6910	6912	an	an	DT	B-NP
O	6913	6922	important	important	JJ	I-NP
O	6923	6927	drug	drug	NN	I-NP
O	6928	6934	target	target	NN	I-NP
O	6935	6937	in	in	IN	B-PP
B-Cell	6938	6947	cancerous	cancerous	JJ	B-NP
I-Cell	6948	6953	cells	cell	NNS	I-NP
O	6953	6954	.	.	.	O

O	6955	6961	Indeed	Indeed	RB	B-ADVP
O	6961	6962	,	,	,	O
O	6963	6965	it	it	PRP	B-NP
O	6966	6969	has	have	VBZ	B-VP
O	6970	6974	been	be	VBN	I-VP
O	6975	6980	shown	show	VBN	I-VP
O	6981	6985	that	that	IN	B-SBAR
O	6986	6995	inhibitor	inhibitor	NN	B-NP
O	6995	6996	-	-	HYPH	B-NP
O	6996	7003	induced	induce	VBN	I-NP
O	7004	7008	TYMS	TYMS	NN	I-NP
O	7009	7013	over	over	AFX	O
O	7013	7014	-	-	HYPH	O
O	7014	7024	expression	expression	NN	B-NP
O	7025	7034	obstructs	obstruct	VBZ	B-VP
O	7035	7038	the	the	DT	B-NP
O	7039	7047	clinical	clinical	JJ	I-NP
O	7048	7058	efficiency	efficiency	NN	I-NP
O	7059	7061	by	by	IN	B-PP
O	7062	7070	inducing	induce	VBG	B-VP
B-Cancer	7071	7076	tumor	tumor	NN	B-NP
O	7077	7081	drug	drug	NN	I-NP
O	7082	7092	resistance	resistance	NN	I-NP
O	7093	7094	[	[	(	O
O	7094	7096	29	29	CD	B-NP
O	7096	7097	]	]	)	O
O	7097	7098	.	.	.	O

O	7099	7101	In	In	IN	B-PP
O	7102	7110	addition	addition	NN	B-NP
O	7111	7113	to	to	TO	B-PP
O	7114	7118	over	over	AFX	B-NP
O	7118	7119	-	-	HYPH	I-NP
O	7119	7129	expression	expression	NN	I-NP
O	7129	7130	,	,	,	O
O	7131	7135	down	down	RB	B-ADVP
O	7135	7136	-	-	HYPH	B-NP
O	7136	7146	regulation	regulation	NN	I-NP
O	7147	7149	of	of	IN	B-PP
O	7150	7154	drug	drug	NN	B-NP
O	7155	7162	targets	target	NNS	I-NP
O	7163	7167	upon	upon	IN	B-PP
O	7168	7175	agonist	agonist	NN	B-NP
O	7176	7185	treatment	treatment	NN	I-NP
O	7186	7189	may	may	MD	B-VP
O	7190	7194	also	also	RB	I-VP
O	7195	7200	cause	cause	VB	I-VP
O	7201	7210	treatment	treatment	NN	B-NP
O	7211	7220	tolerance	tolerance	NN	I-NP
O	7221	7223	as	as	IN	B-SBAR
O	7224	7232	observed	observe	VBN	B-VP
O	7233	7236	for	for	IN	B-PP
O	7237	7242	ADRB2	ADRB2	NN	B-NP
O	7243	7247	long	long	JJ	I-NP
O	7247	7248	-	-	HYPH	B-NP
O	7248	7254	acting	act	VBG	I-NP
O	7255	7262	agonist	agonist	NN	I-NP
O	7263	7272	treatment	treatment	NN	I-NP
O	7272	7273	.	.	.	O

O	7274	7279	ADRB2	ADRB2	NN	B-NP
O	7280	7282	is	be	VBZ	B-VP
O	7283	7284	a	a	DT	B-NP
O	7285	7296	therapeutic	therapeutic	JJ	I-NP
O	7297	7303	target	target	NN	I-NP
O	7304	7313	activated	activate	VBN	B-VP
O	7314	7316	to	to	TO	I-VP
O	7317	7322	treat	treat	VB	I-VP
O	7323	7326	the	the	DT	B-NP
O	7327	7335	symptoms	symptom	NNS	I-NP
O	7336	7338	of	of	IN	B-PP
O	7339	7345	asthma	asthma	NN	B-NP
O	7345	7346	.	.	.	O

O	7347	7349	We	We	PRP	B-NP
O	7350	7357	observe	observe	VBP	B-VP
O	7358	7361	the	the	DT	B-NP
O	7362	7369	agonist	agonist	NN	I-NP
O	7369	7370	-	-	HYPH	O
O	7370	7377	induced	induce	VBN	B-VP
O	7378	7380	up	up	RB	B-ADVP
O	7380	7381	-	-	HYPH	B-NP
O	7381	7391	regulation	regulation	NN	I-NP
O	7392	7394	of	of	IN	B-PP
O	7395	7400	ADRB2	ADRB2	NN	B-NP
O	7401	7404	and	and	CC	O
O	7405	7412	already	already	RB	B-ADVP
O	7413	7415	in	in	IN	B-PP
O	7416	7420	2005	2005	CD	B-NP
O	7420	7421	,	,	,	O
O	7422	7425	the	the	DT	B-NP
O	7426	7429	FDA	FDA	NNP	I-NP
O	7430	7436	warned	warn	VBD	B-VP
O	7437	7445	patients	patient	NNS	B-NP
O	7446	7450	that	that	IN	B-SBAR
O	7451	7456	ADRB2	ADRB2	NN	B-NP
O	7457	7462	might	might	MD	B-VP
O	7463	7465	be	be	VB	I-VP
O	7466	7470	down	down	RB	B-ADVP
O	7470	7471	-	-	HYPH	O
O	7471	7480	regulated	regulate	VBN	B-VP
O	7481	7482	(	(	(	O
O	7482	7497	desensitization	desensitization	NN	B-NP
O	7497	7498	)	)	)	O
O	7499	7502	and	and	CC	O
O	7503	7505	be	be	VB	B-VP
O	7506	7518	unresponsive	unresponsive	JJ	B-ADJP
O	7519	7522	for	for	IN	B-PP
O	7523	7529	asthma	asthma	NN	B-NP
O	7530	7539	treatment	treatment	NN	I-NP
O	7540	7543	due	due	IN	B-PP
O	7544	7546	to	to	TO	B-VP
O	7547	7551	long	long	RB	I-VP
O	7551	7552	-	-	HYPH	I-VP
O	7552	7558	acting	act	VBG	I-VP
O	7559	7566	agonist	agonist	NN	B-NP
O	7567	7575	exposure	exposure	NN	I-NP
O	7576	7577	[	[	(	O
O	7577	7579	20	20	CD	B-NP
O	7579	7580	]	]	)	O
O	7580	7581	,	,	,	O
O	7582	7583	[	[	(	O
O	7583	7585	30	30	CD	B-NP
O	7585	7586	]	]	)	O
O	7586	7587	.	.	.	O

O	7588	7592	Thus	Thus	RB	B-ADVP
O	7592	7593	,	,	,	O
O	7594	7604	robustness	robustness	NN	B-NP
O	7605	7607	in	in	IN	B-PP
O	7608	7618	biological	biological	JJ	B-NP
O	7619	7626	systems	system	NNS	I-NP
O	7627	7632	could	could	MD	B-VP
O	7633	7640	prevent	prevent	VB	I-VP
O	7641	7644	the	the	DT	B-NP
O	7645	7658	applicability	applicability	NN	I-NP
O	7659	7661	of	of	IN	B-PP
O	7662	7665	the	the	DT	B-NP
O	7666	7670	long	long	JJ	I-NP
O	7670	7671	-	-	HYPH	I-NP
O	7671	7675	term	term	NN	I-NP
O	7676	7686	treatments	treatment	NNS	I-NP
O	7687	7690	via	via	IN	B-PP
O	7691	7699	positive	positive	JJ	B-NP
O	7699	7700	/	/	SYM	I-NP
O	7700	7708	negative	negative	JJ	I-NP
O	7709	7717	feedback	feedback	NN	I-NP
O	7718	7723	loops	loop	VBZ	B-VP
O	7724	7726	of	of	IN	B-PP
O	7727	7730	the	the	DT	B-NP
O	7731	7735	drug	drug	NN	I-NP
O	7736	7742	target	target	NN	I-NP
O	7743	7752	affecting	affect	VBG	B-VP
O	7753	7756	the	the	DT	B-NP
O	7757	7765	clinical	clinical	JJ	I-NP
O	7766	7776	efficiency	efficiency	NN	I-NP
O	7777	7779	of	of	IN	B-PP
O	7780	7785	drugs	drug	NNS	B-NP
O	7786	7788	in	in	IN	B-PP
O	7789	7794	trial	trial	NN	B-NP
O	7795	7798	and	and	CC	B-PP
O	7799	7801	on	on	IN	B-PP
O	7802	7805	the	the	DT	B-NP
O	7806	7812	market	market	NN	I-NP
O	7812	7813	.	.	.	O

O	7814	7818	Drug	Drug	NN	B-NP
O	7818	7819	-	-	HYPH	B-PP
O	7819	7826	induced	induce	VBN	B-NP
O	7827	7837	regulation	regulation	NN	I-NP
O	7838	7840	of	of	IN	B-PP
O	7841	7845	drug	drug	NN	B-NP
O	7846	7853	targets	target	NNS	I-NP
O	7854	7857	can	can	MD	B-VP
O	7858	7862	thus	thus	RB	I-VP
O	7863	7865	be	be	VB	I-VP
O	7866	7872	linked	link	VBN	I-VP
O	7873	7875	to	to	TO	B-PP
O	7876	7885	tolerance	tolerance	NN	B-NP
O	7886	7897	development	development	NN	I-NP
O	7897	7898	,	,	,	O
O	7899	7904	which	which	WDT	B-NP
O	7905	7914	restricts	restrict	VBZ	B-VP
O	7915	7918	the	the	DT	B-NP
O	7919	7929	efficiency	efficiency	NN	I-NP
O	7930	7932	of	of	IN	B-PP
O	7933	7941	clinical	clinical	JJ	B-NP
O	7942	7952	treatments	treatment	NNS	I-NP
O	7953	7958	where	where	WRB	B-ADVP
O	7959	7962	the	the	DT	B-NP
O	7963	7967	drug	drug	NN	I-NP
O	7968	7981	concentration	concentration	NN	I-NP
O	7982	7984	is	be	VBZ	B-VP
O	7985	7992	limited	limit	VBN	I-VP
O	7993	7995	to	to	TO	I-VP
O	7996	8001	avoid	avoid	VB	I-VP
O	8002	8004	an	an	DT	B-NP
O	8005	8011	excess	excess	NN	I-NP
O	8012	8014	of	of	IN	B-PP
O	8015	8022	adverse	adverse	JJ	B-NP
O	8023	8027	drug	drug	NN	I-NP
O	8028	8037	reactions	reaction	NNS	I-NP
O	8037	8038	.	.	.	O

O	8039	8044	Taken	Take	VBN	B-VP
O	8045	8053	together	together	RB	B-ADVP
O	8053	8054	,	,	,	O
O	8055	8057	we	we	PRP	B-NP
O	8058	8062	have	have	VBP	B-VP
O	8063	8073	identified	identify	VBN	I-VP
O	8074	8078	drug	drug	NN	B-NP
O	8078	8079	-	-	HYPH	B-VP
O	8079	8086	induced	induce	VBN	B-NP
O	8087	8099	differential	differential	JJ	I-NP
O	8100	8110	regulation	regulation	NN	I-NP
O	8111	8113	of	of	IN	B-PP
O	8114	8118	drug	drug	NN	B-NP
O	8119	8126	targets	target	NNS	I-NP
O	8126	8127	.	.	.	O

O	8128	8131	Due	Due	JJ	B-PP
O	8132	8134	to	to	TO	I-PP
O	8135	8138	the	the	DT	B-NP
O	8139	8146	limited	limited	JJ	I-NP
O	8147	8153	signal	signal	NN	I-NP
O	8154	8156	to	to	TO	B-VP
O	8157	8162	noise	noise	VB	I-VP
O	8163	8168	ratio	ratio	NN	B-NP
O	8169	8171	in	in	IN	B-PP
O	8172	8175	the	the	DT	B-NP
O	8176	8180	data	datum	NNS	I-NP
O	8181	8183	at	at	IN	B-PP
O	8184	8188	hand	hand	NN	B-NP
O	8188	8189	,	,	,	O
O	8190	8193	the	the	DT	B-NP
O	8194	8204	identified	identify	VBN	I-NP
O	8205	8206	8	8	CD	I-NP
O	8206	8207	%	%	NN	I-NP
O	8208	8210	of	of	IN	B-PP
O	8211	8214	all	all	DT	B-NP
O	8215	8219	drug	drug	NN	I-NP
O	8220	8227	targets	target	NNS	I-NP
O	8228	8232	that	that	WDT	B-NP
O	8233	8237	show	show	VBP	B-VP
O	8238	8246	feedback	feedback	NN	B-NP
O	8247	8252	loops	loop	NNS	I-NP
O	8253	8256	has	have	VBZ	B-VP
O	8257	8259	to	to	TO	I-VP
O	8260	8262	be	be	VB	I-VP
O	8263	8267	seen	see	VBN	I-VP
O	8268	8270	as	as	IN	B-PP
O	8271	8272	a	a	DT	B-NP
O	8273	8278	lower	low	JJR	I-NP
O	8279	8284	limit	limit	NN	I-NP
O	8284	8285	,	,	,	O
O	8286	8287	i	i	NN	B-NP
O	8287	8288	.	.	.	O
O	8288	8289	e	e	NN	B-NP
O	8289	8290	.	.	.	I-NP
O	8291	8297	target	target	NN	I-NP
O	8297	8298	-	-	HYPH	O
O	8298	8308	regulation	regulation	NN	B-NP
O	8309	8316	appears	appear	VBZ	B-VP
O	8317	8319	as	as	IN	B-PP
O	8320	8321	a	a	DT	B-NP
O	8322	8326	wide	wide	JJ	I-NP
O	8326	8327	-	-	HYPH	I-NP
O	8327	8333	spread	spread	NN	I-NP
O	8334	8344	biological	biological	JJ	I-NP
O	8345	8355	phenomenon	phenomenon	NN	I-NP
O	8356	8360	that	that	WDT	B-NP
O	8361	8364	has	have	VBZ	B-VP
O	8365	8367	to	to	TO	I-VP
O	8368	8370	be	be	VB	I-VP
O	8371	8376	taken	take	VBN	I-VP
O	8377	8381	into	into	IN	B-PP
O	8382	8389	account	account	NN	B-NP
O	8390	8396	during	during	IN	B-PP
O	8397	8401	drug	drug	NN	B-NP
O	8402	8413	development	development	NN	I-NP
O	8413	8414	.	.	.	O

